• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经内分泌肿瘤诊断前的既往症状和医疗保健利用:一项 SEER-Medicare 数据库研究。

Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study.

机构信息

Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, USA.

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA.

出版信息

Sci Rep. 2018 Nov 15;8(1):16863. doi: 10.1038/s41598-018-35340-4.

DOI:10.1038/s41598-018-35340-4
PMID:30442902
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6238007/
Abstract

The incidence and prevalence of neuroendocrine tumors (NETs) are continually increasing. While it is known that NET symptoms often predate diagnosis, their prevalence and impact on resource utilization and costs are largely unknown. We identified 9,319 elderly patients diagnosed with NETs between 1/2003 and 12/2011 from the Surveillance, Epidemiology and End Results (SEER)-Medicare. We examined the patients' conditions potentially associated with NET, resource utilization and costs during the year before diagnosis. We found that NET patients were more likely to have diagnoses of hypertension (63.8% vs. 53.3%), abdominal pain (22.2% vs. 7.6%), heart failure (11.7% vs. 8.0%), diarrhea (5.8% vs. 1.8%), peripheral edema (5.4% vs. 3.8%) and irritable bowel syndrome (1.2% vs. 0.5%) compared to the non-cancer control group. They also had much higher resource utilization including number of outpatient visits (mean: 22.1 vs. 17.2), percentage with ER visits (20.9% vs. 11.6%), and hospitalizations (28.4% vs. 17.0%). Similarly, NET patients incurred significantly higher total (mean: $14602 vs. $9464), outpatient (mean: $5987 vs. $4253), and inpatient costs (mean: $8615 vs. $5211). This first population-based study on the pre-diagnosis symptoms and healthcare utilization found that NET patients were more likely to have certain conditions and incur higher resource utilizations and costs.

摘要

神经内分泌肿瘤(NET)的发病率和患病率持续上升。虽然已知 NET 症状通常先于诊断出现,但它们的患病率及其对资源利用和成本的影响在很大程度上尚不清楚。我们从监测、流行病学和最终结果(SEER)-医疗保险数据库中确定了 9319 名在 2003 年 1 月至 2011 年 12 月期间被诊断为 NET 的老年患者。我们研究了患者在诊断前一年可能与 NET 相关的疾病、资源利用和成本情况。我们发现,NET 患者更有可能被诊断出患有高血压(63.8%比 53.3%)、腹痛(22.2%比 7.6%)、心力衰竭(11.7%比 8.0%)、腹泻(5.8%比 1.8%)、外周水肿(5.4%比 3.8%)和肠易激综合征(1.2%比 0.5%)。与非癌症对照组相比,他们的资源利用也更高,包括门诊就诊次数(平均:22.1 比 17.2)、急诊就诊比例(20.9%比 11.6%)和住院率(28.4%比 17.0%)。同样,NET 患者的总费用(平均:$14602 比 $9464)、门诊费用(平均:$5987 比 $4253)和住院费用(平均:$8615 比 $5211)也显著更高。这是第一项关于 NET 患者诊断前症状和医疗保健利用情况的基于人群的研究,发现 NET 患者更有可能患有某些疾病,并产生更高的资源利用和成本。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc23/6238007/3cb252afca2c/41598_2018_35340_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc23/6238007/3cb252afca2c/41598_2018_35340_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dc23/6238007/3cb252afca2c/41598_2018_35340_Fig1_HTML.jpg

相似文献

1
Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study.神经内分泌肿瘤诊断前的既往症状和医疗保健利用:一项 SEER-Medicare 数据库研究。
Sci Rep. 2018 Nov 15;8(1):16863. doi: 10.1038/s41598-018-35340-4.
2
Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.监测、流行病学和最终结果计划(SEER)医疗保险受益的非小细胞肺癌(NSCLC)患者中与慢性阻塞性肺疾病(COPD)相关的医疗保健利用和费用
J Med Econ. 2018 Sep;21(9):861-868. doi: 10.1080/13696998.2018.1484370. Epub 2018 Jul 2.
3
Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients.类癌综合征与老年患者神经内分泌肿瘤诊断后第一年的治疗费用。
Oncologist. 2017 Dec;22(12):1451-1462. doi: 10.1634/theoncologist.2017-0149. Epub 2017 Jun 22.
4
Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors.老年神经内分泌肿瘤患者的癌症护理成本。
Pharmacoeconomics. 2018 Aug;36(8):1005-1013. doi: 10.1007/s40273-018-0656-z.
5
First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA.美国胃肠道神经内分泌肿瘤(GI NETs)患者的一线全身治疗依从性、医疗资源利用及成本
J Med Econ. 2018 Aug;21(8):821-826. doi: 10.1080/13696998.2018.1474748. Epub 2018 May 25.
6
Treatment adherence, healthcare resource utilization, and costs in patients with lung neuroendocrine tumors (lung NETs) in the USA.美国肺神经内分泌肿瘤(肺 NET)患者的治疗依从性、医疗资源利用和成本。
Curr Med Res Opin. 2018 Dec;34(12):2151-2156. doi: 10.1080/03007995.2018.1505277. Epub 2018 Aug 10.
7
Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.前列腺癌患者临终前一年的资源使用情况对比研究。 (注:原文中“Versus of Prostate Cancer”表述有误,推测可能是“Versus Without Prostate Cancer”之类的表述,这里按字面翻译了)
Clin Genitourin Cancer. 2016 Feb;14(1):28-37.e2. doi: 10.1016/j.clgc.2015.07.006. Epub 2015 Aug 6.
8
Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer.老年女性乳腺癌患者初始治疗阶段的医疗利用和费用。
J Natl Compr Canc Netw. 2017 Nov;15(11):1401-1409. doi: 10.6004/jnccn.2017.0167.
9
Neuroendocrine tumor epidemiology: contrasting Norway and North America.神经内分泌肿瘤流行病学:挪威与北美的对比
Cancer. 2008 Nov 15;113(10):2655-64. doi: 10.1002/cncr.23883.
10
Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.老年人高危和转移性黑色素瘤的直接经济负担:来自SEER-Medicare关联数据库的证据。
Appl Health Econ Health Policy. 2009;7(1):31-41. doi: 10.1007/BF03256140.

引用本文的文献

1
Patterns of emergency department visits before diagnosis with digestive neuroendocrine neoplasms.在诊断为消化系统神经内分泌肿瘤之前,急诊科就诊的模式。
Int J Colorectal Dis. 2023 May 31;38(1):148. doi: 10.1007/s00384-023-04443-4.
2
Update on Prevalence of Pain in Patients with Cancer 2022: A Systematic Literature Review and Meta-Analysis.《2022年癌症患者疼痛患病率最新情况:系统文献综述与荟萃分析》
Cancers (Basel). 2023 Jan 18;15(3):591. doi: 10.3390/cancers15030591.
3
Role of Combined Ga DOTA-Peptides and F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms.

本文引用的文献

1
Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs.患者报告的神经内分泌肿瘤(NET)诊断负担:NET患者首次全球调查结果
J Glob Oncol. 2016 Jun 8;3(1):43-53. doi: 10.1200/JGO.2015.002980. eCollection 2017 Feb.
2
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.美国神经内分泌肿瘤患者的发病率、患病率和生存结局趋势。
JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589.
3
Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.
镓标记的DOTA肽与氟代脱氧葡萄糖PET/CT联合应用在胃肠胰神经内分泌肿瘤评估中的作用
Diagnostics (Basel). 2022 Jan 22;12(2):280. doi: 10.3390/diagnostics12020280.
4
The synergistic effects of TGF-β1 and RUNX2 on enamel mineralization through regulating ODAPH expression during the maturation stage.TGF-β1 和 RUNX2 通过调节成熟阶段 ODAPH 的表达对牙釉质矿化的协同作用。
J Mol Histol. 2022 Apr;53(2):483-492. doi: 10.1007/s10735-022-10060-2. Epub 2022 Feb 14.
5
Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest).使用液体活检多基因组 mRNA 特征(NETest)对神经内分泌肿瘤切除术后残留疾病进行早期鉴定。
Ann Surg Oncol. 2021 Nov;28(12):7506-7517. doi: 10.1245/s10434-021-10021-1. Epub 2021 May 18.
6
Evaluating cost-effectiveness in the management of neuroendocrine neoplasms.评估神经内分泌肿瘤管理的成本效益。
Rev Endocr Metab Disord. 2021 Sep;22(3):647-663. doi: 10.1007/s11154-020-09608-y. Epub 2020 Nov 6.
7
Racial/Ethnic Disparities and Survival Characteristics in Non-Pancreatic Gastrointestinal Tract Neuroendocrine Tumors.非胰腺胃肠道神经内分泌肿瘤的种族/民族差异及生存特征
Cancers (Basel). 2020 Oct 15;12(10):2990. doi: 10.3390/cancers12102990.
8
Symptoms in Blastomycosis, Coccidioidomycosis, and Histoplasmosis Versus Other Respiratory Illnesses in Commercially Insured Adult Outpatients-United States, 2016-2017.荚膜组织胞浆菌病、球孢子菌病和组织胞浆菌病与商业保险成年门诊患者其他呼吸道疾病的症状比较——美国,2016-2017 年。
Clin Infect Dis. 2021 Dec 6;73(11):e4336-e4344. doi: 10.1093/cid/ciaa1554.
9
The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors.多基因液体活检(NETest)在神经内分泌肿瘤中的临床应用。
Adv Med Sci. 2020 Mar;65(1):18-29. doi: 10.1016/j.advms.2019.10.002. Epub 2019 Dec 13.
神经内分泌肿瘤诊断时类癌综合征的发生率:一项基于人群的研究。
Lancet Oncol. 2017 Apr;18(4):525-534. doi: 10.1016/S1470-2045(17)30110-9. Epub 2017 Feb 24.
4
Pathways to Lung Cancer Diagnosis: A Qualitative Study of Patients and General Practitioners about Diagnostic and Pretreatment Intervals.肺癌诊断途径:一项关于诊断和治疗前间隔的患者和全科医生的定性研究。
Ann Am Thorac Soc. 2017 May;14(5):742-753. doi: 10.1513/AnnalsATS.201610-817OC.
5
Understanding pathways to breast cancer diagnosis among women in the Western Cape Province, South Africa: a qualitative study.了解南非西开普省女性乳腺癌诊断途径:一项定性研究。
BMJ Open. 2016 Jan 4;6(1):e009905. doi: 10.1136/bmjopen-2015-009905.
6
Symptom appraisal and healthcare-seeking for symptoms suggestive of colorectal cancer: a qualitative study.对提示结直肠癌症状的症状评估及就医行为:一项定性研究。
BMJ Open. 2015 Oct 9;5(10):e008448. doi: 10.1136/bmjopen-2015-008448.
7
Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.世界卫生组织2000/2004年与世界卫生组织2010年胃肠道和胰腺神经内分泌肿瘤分类的比较。
Ann Diagn Pathol. 2015 Apr;19(2):81-7. doi: 10.1016/j.anndiagpath.2015.01.001. Epub 2015 Jan 9.
8
Consensus guidelines for the management and treatment of neuroendocrine tumors.神经内分泌肿瘤管理与治疗的共识指南。
Pancreas. 2013 May;42(4):557-77. doi: 10.1097/MPA.0b013e31828e34a4.
9
Clinical aspects, diagnostic challenges and management of patients with neuroendocrine tumors (NETs).神经内分泌肿瘤(NETs)患者的临床特征、诊断挑战及管理
Onkologie. 2011;34(3):139-46. doi: 10.1159/000324778. Epub 2011 Feb 21.
10
NANETS consensus guidelines for the diagnosis of neuroendocrine tumor.神经内分泌肿瘤诊断的NANETS共识指南。
Pancreas. 2010 Aug;39(6):713-34. doi: 10.1097/MPA.0b013e3181ebaffd.